

The Apothecaries' Prize

To mark the 400th Anniversary of the granting of its Royal Charter by King James I in 1617, the Society of Apothecaries established an appeal fund for making grants in three areas. One of these was the support of the newly established Apothecaries' Prize.

The Prize is aimed at doctors at pre-consultant level, i.e. within the last two-three years of training, or, in pharmacy training, those practising at Advanced Stage II of the Royal Pharmaceutical Society's Faculty or similar. Medical candidates will normally be in a specialist registrar training programme.

Candidates are asked to submit:

1. A published paper in medical therapeutics or public health medicine. The topic may be in any specialist medical, surgical, psychiatric, public health or pharmaceutical field. It may be clinical or scientific, but should relate to therapy or public health. The applicant should be first, last or principal author on the paper. The paper should have been published within the preceding two years.
2. A statement by the candidate outlining the significance of the paper and his/her contribution to it.
3. A written independent peer review, solicited by the applicant, indicating the quality and importance of the paper. The reviewer should not work in the same institution as the applicant.
4. Evidence of the candidate's stage of career.
5. A statement by a sponsor confirming the significance of the paper and the candidate's contribution to it. The sponsor could be the candidate's supervisor or another senior colleague.

The Prize has been awarded to the following for their work on the research paper listed:

2018 Dr Lauren WALKER– *“Molecular isoforms of high-mobility group box 1 mechanistic biomarkers for epilepsy.”* Clinical & Investigative Medicine. 2017; 127 (6):2118–2132 * This paper was retracted and the Prize re-awarded for *“High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: a proof-of-concept study”*. Epilepsia (2021); 10.1111/epi.17116 <https://onlinelibrary.wiley.com/doi/epdf/10.1111/epi.17116>

2019 Dr Aran SINGANAYAGAM – *“Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.”* Nature Communications 2018; 9 2229. <https://www.nature.com/articles/s41467-018-04574-1>

2020 Dr Yin WU – “An innate-like V δ 1+ $\gamma\delta$ T cell compartment in the human breast is associated with remission in triple-negative breast cancer”, *Science Translational Medicine* 11 (2019). <https://pubmed.ncbi.nlm.nih.gov/31597756/>

2021 Mr Jonathan EVANS - “How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up”. *The Lancet* 2019; 393, 647-654 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)31665-9/fulltext#:~:text=Assuming%20that%20estimates%20from%20national,in%20around%2058%25%20of%20patients.](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31665-9/fulltext#:~:text=Assuming%20that%20estimates%20from%20national,in%20around%2058%25%20of%20patients.)

2022 Dr Paul VULLIAMY - *Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. Proceedings of the National Academy of Sciences USA. 2019; 116(35):17444-17444.* <https://pubmed.ncbi.nlm.nih.gov/31405966/>

2023 Dr Sizheng (Steven) ZHAO - *Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.* *Rheumatology (Oxford).* 2022; Mar 31. <https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac190/6561554>